Doravirine/lamivudine/tenofovir disoproxil fumarate

Doravirine/lamivudine/tenofovir disoproxil fumarate
Combination of
Doravirine	non-nucleoside reverse transcriptase inhibitor
Lamivudine	nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil fumarate	nucleotide reverse transcriptase inhibitor tenofovir disoproxil fumarate
Clinical data
Trade names	Delstrigo
Synonyms	MK-1439A

Doravirine/lamivudine/tenofovir disoproxil fumarate (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS.^[1] It contains doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).^[2] In the United States, it was approved by the Food and Drug Administration in August 2018 for the treatment of HIV-1 infection.^[2]

References

↑ "Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co". Adis Insight.
1 2 "FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. August 30, 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co". Adis Insight.

[Merck-2] 1 2 "FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. August 30, 2018.